VR for Symptom Control and Wellbeing

November 20, 2023 updated by: Royal Cornwall Hospitals Trust

The Use of Virtual Reality for Symptom Control and Wellbeing in Palliative Care and Oncology Patients

To investigate the effect that a Virtual Reality experience can have on patient symptoms and wellbeing for palliative care and oncology inpatients

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United Kingdom
    • Cornwall
      • Truro, Cornwall, United Kingdom, TR1 3HD
        • Royal Cornwall Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion criteria

  • > 18 years of age
  • Inpatient at RCHT know to the palliative care team
  • Able to consent
  • Able to speak and understand the English language
  • Able to use the virtual reality system
  • Able to complete ESAS-r Questionnaire

Exclusion criteria

  • <18 years of age
  • Patient unable to consent
  • Patient unable to speak English
  • Unable to use the virtual reality system (e.g. visually impaired)
  • Known Epilepsy or seizures or suspected predisposition to seizures (e.g. Brain metastasis)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Virtual Reality Headset
VR headset, programmed with a selection of 7 wellbeing programs to identify if use will improve participants wellbeing
Device: Virtual Reality Headset to provide a Virtual Reality Experience
Participants will utilise a Virtual Reality experience for distraction therapy via a Virtual reality headset. Participants will wear the Virtual reality headset to be immersed in a multimedia experience.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
ESAS-r Quality of Life Scores
Time Frame: Time 0 & Time 60 minutes
Change in ESAS-r QoL score between start and finish of Virtual Reality experience. 0 = No symptoms to 10 = Worst Symptom
Time 0 & Time 60 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quantitative clinician experience of VR intervention
Time Frame: Time 60 minutes
Clinician score of patient experience using Virtual Reality intervention for symptoms and wellbeing between 0 (negative) and 10 (positive)
Time 60 minutes
Quantitative clinician experience of VR intervention
Time Frame: Time 60 minutes
Patient score of experience using Virtual Reality intervention for symptoms and wellbeing between 0 (negative) and 10 (positive)
Time 60 minutes

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Qualitative patient experience of VR interventions
Time Frame: Time 60 minutes
Patients to answer: Were there any negative side effects of the VR session?
Time 60 minutes
Repeat VR experiences
Time Frame: 12 Months
ESAS-r QoL Scores (0 to 10) will be collected each time a patient uses the experience to consider the effect repeat exposure has on wellbeing and symptoms. 0 = No symptoms to 10 = Worst Symptom
12 Months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Royal Cornwall Hospitals Trust

Investigators

  • Principal Investigator: Niall O Moon, BMBCh, doctor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 14, 2021

Primary Completion (Actual)

September 20, 2022

Study Completion (Actual)

September 20, 2022

Study Registration Dates

First Submitted

March 23, 2021

First Submitted That Met QC Criteria

March 25, 2021

First Posted (Actual)

March 29, 2021

Study Record Updates

Last Update Posted (Estimated)

November 21, 2023

Last Update Submitted That Met QC Criteria

November 20, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2021.RCHT.07

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

No plan to share patient data

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Palliative Care

Clinical Trials on Virtual Reality Headset to provide a Virtual Reality Experience

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe